keyword
MENU ▼
Read by QxMD icon Read
search

nsclc brain radiotherapy

keyword
https://www.readbyqxmd.com/read/28076323/clinical-outcome-of-tyrosine-kinase-inhibitors-alone-or-combined-with-radiotherapy-for-brain-metastases-from-epidermal-growth-factor-receptor-egfr-mutant-non-small-cell-lung-cancer-nsclc
#1
Qianqian Zhu, Yanan Sun, Yingying Cui, Ke Ye, Chengliang Yang, Daoke Yang, Jie Ma, Xiao Liu, Jinming Yu, Hong Ge
This study compared treatment outcomes between TKI monotherapy and TKI administration combined with brain radiotherapy (TKI + RT) in 133 non-small cell lung cancer (NSCLC) patients with brain metastasis (BM). We also evaluated the association of different epidermal growth factor receptor (EGFR) mutation subtypes with treatment outcome. To screen for potential variables affecting cranial progression free survival (PFS) and overall survival (OS), we performed univariate and multivariate analysis based on Cox proportional-hazards models...
January 5, 2017: Oncotarget
https://www.readbyqxmd.com/read/28074321/predictive-factors-of-early-distant-brain-failure-after-gamma-knife-radiosurgery-alone-in-patients-with-brain-metastases-of-non-small-cell-lung-cancer
#2
Young Cheol Na, Hyun Ho Jung, Hye Ryun Kim, Byoung Chul Cho, Jin Woo Chang, Yong Gou Park, Won Seok Chang
The objective of this study was to elucidate the predictive factors for early distant brain failure in patients with brain metastases of non-small-cell lung cancer (NSCLC) who were treated with gamma knife radiosurgery (GKRS) without previous whole-brain radiotherapy (WBRT) or surgery. We retrospectively reviewed clinical and imaging data of 459 patients with brain metastases of NSCLC who underwent GKRS from June 2008 to December 2013. The primary end-point was early distant brain failure, defined as the detection of newly developed metastatic lesions on magnetic resonance imaging (MRI) 3 months after GKRS...
January 10, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28068937/the-efficacy-and-roles-of-combining-temozolomide-with-whole-brain-radiotherapy-in-protection-neurocognitive-function-and-improvement-quality-of-life-of-non-small-cell-lung-cancer-patients-with-brain-metastases
#3
Xia Deng, Zhen Zheng, Baochai Lin, Huafang Su, Hanbin Chen, Shaoran Fei, Zhenghua Fei, Lihao Zhao, Xiance Jin, Cong-Ying Xie
BACKGROUND: Brain metastasis (BM) is a poor prognostic factor for non-small-cell lung cancer (NSCLC). The efficacy and roles of combining temozolomide (TMZ) with whole brain radiotherapy (WBRT) in protection neurocognitive function (NCF) and improvement quality of life (QOL) were investigated and compared with WBRT alone in the treatment of NSCLC patients with BM. METHODS: A total of 238 NSCLC patients with BM were reviewed and categorized into WBRT plus TMZ (RCT) arm and WBRT alone (RT), respectively...
January 10, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28066650/whole-brain-radiotherapy-for-brain-metastases-from-non-small-cell-lung-cancer-the-end-of-an-era
#4
COMMENT
Anna M E Bruynzeel, Frank J Lagerwaard
No abstract text is available yet for this article.
November 2016: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28031389/systemic-therapy-of-brain-metastases-non-small-cell-lung-cancer-breast-cancer-and-melanoma
#5
REVIEW
Marc C Chamberlain, Christina S Baik, Vijayakrishna K Gadi, Shailender Bhatia, Laura Q M Chow
Brain metastases (BM) occur frequently in many cancers, particularly non-small cell lung cancer (NSCLC), breast cancer, and melanoma. The development of BM is associated with poor prognosis and has an adverse impact on survival and quality of life. Commonly used therapies for BM such as surgery or radiotherapy are associated with only modest benefits. However, recent advances in systemic therapy of many cancers have generated considerable interest in exploration of those therapies for treatment of intracranial metastases...
January 2017: Neuro-oncology
https://www.readbyqxmd.com/read/27998469/-epidermal-growth-factor-tyrosine-kinase-inhibitors-used-in-the-treatment-of-nsclc-patients-with-leptomeningeal-metastasis
#6
Y Xu, W Zhong, J Zhao, M J Chen, L Zhang, L Y Li, M Z Wang
Objective: The aim of this study was to identify the clinical features and prognostic factors of leptomeningeal metastasis (LM) in non-small cell lung cancer (NSCLC) patients undergoing treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). Methods: Twenty-five cases of NSCLC with LM, treated in our hospital during January 1, 2003 to October 31, 2013, were enrolled in this study. Medical records were reviewed for clinical features and treatments, and the survival and prognostic factors were analyzed...
December 23, 2016: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/27969459/mini01-11-radiotherapy-plus-egfr-tkis-for-brain-metastasis-in-egfr-mutant-non-small-cell-lung-cancer-a-retrospective-analysis-of-a-single-institution-topic-medical-oncology
#7
Jiexia Zhang, Xiaoshun Shi, Di Cai, Xiaoxiang Li, Zhuolin Wu, Ying Liang, Yinyin Qin, Chengzhi Zhou, Jianxing He
No abstract text is available yet for this article.
November 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27955888/stereotactic-radiotherapy-following-surgery-for-brain-metastasis-predictive-factors-for-local-control-and-radionecrosis
#8
M Doré, S Martin, G Delpon, K Clément, L Campion, F Thillays
PURPOSE: To evaluate local control and adverse effects after postoperative hypofractionated stereotactic radiosurgery in patients with brain metastasis. METHODS: We reviewed patients who had hypofractionated stereotactic radiosurgery (7.7Gy×3 prescribed to the 70% isodose line, with 2mm planning target volume margin) following resection from March 2008 to January 2014. The primary endpoint was local failure defined as recurrence within the surgical cavity. Secondary endpoints were distant failure rates and the occurrence of radionecrosis...
December 7, 2016: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/27806449/advances-in-radiotherapy-technology-for-non-small-cell-lung-cancer-what-every-general-practitioner-should-know
#9
Michael Huo, Peter Gorayski, Mark B Pinkham, Margot Lehman
BACKGROUND: Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related death in Australia. Radiotherapy plays an important role in the curative and palliative settings. OBJECTIVE: This article reviews recent technological advances that have expanded the radiotherapy treatment options available, and presents standard and emerging approaches to NSCLC. DISCUSSION: General practitioners play an integral role in the care and education of patients during diagnosis, treatment and
follow-up of NSCLC...
November 2016: Australian Family Physician
https://www.readbyqxmd.com/read/27755835/effects-of-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors-alone-on-egfr-mutant-non-small-cell-lung-cancer-with-brain-metastasis
#10
Qiuyi Zhang, Xuchao Zhang, Honghong Yan, Benyuan Jiang, Chongrui Xu, Jinji Yang, Zhihong Chen, Jian Su, Yi-Long Wu, Qing Zhou
BACKGROUND: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are remarkably effective for treating EGFR-mutant non-small cell lung cancer (NSCLC). However, the individual role of EGFR-TKIs in patients with brain metastasis (BM) arising from EGFR-mutant NSCLC remains unclear. METHODS: Patients with BM secondary to NSCLC and harboring EGFR-activating mutations were retrospectively screened. Patients who received gefitinib or erlotinib to control both extracranial lesions (ECLs) and intracranial lesions (ICLs) were eligible...
November 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27682542/whole-brain-radiotherapy-has-no-effect-in-patients-whose-lung-cancer-has-spread
#11
(no author information available yet)
Whole brain radiotherapy makes little or no difference to survival rates or quality of life in patients with non-small cell lung cancer (NSCLC) that has spread to the brain, say researchers.
September 28, 2016: Nursing Standard
https://www.readbyqxmd.com/read/27663395/whole-brain-radiotherapy-for-patients-with-non-small-cell-lung-cancer-with-egfr-mutations-why-and-when
#12
EDITORIAL
Rafal Dziadziuszko
No abstract text is available yet for this article.
October 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27621899/a-case-of-long-term-survival-after-multimodal-local-treatments-of-intramedullary-spinal-cord-metastasis-of-squamous-cell-lung-cancer
#13
Shojiro Minomo, Akihiro Tokoro, Tomoki Utsumi, Masahiro Ishihara, Masanori Akira, Shinji Atagi
Intramedullary spinal cord metastasis of non-small cell lung cancer is rare, and it has a short prognosis. We report a 53-year-old man diagnosed with cT4N0M0, stage IIIA squamous cell lung cancer. Ten months after left pneumonectomy (pT4N0M0), an intramedullary spinal cord tumor developed at the axis level. The intramedullary spinal cord tumor was resected, and he was diagnosed with metastatic squamous cell lung cancer. Radiotherapies and another tumor resection were conducted, as he had a good performance status and the discrete lesion was associated with the risk of brain stem compression...
August 2016: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/27604505/whole-brain-radiotherapy-in-patients-with-nsclc-and-brain-metastases
#14
COMMENT
Cécile Le Pechoux, Frederic Dhermain, Benjamin Besse
No abstract text is available yet for this article.
October 22, 2016: Lancet
https://www.readbyqxmd.com/read/27604504/dexamethasone-and-supportive-care-with-or-without-whole-brain-radiotherapy-in-treating-patients-with-non-small-cell-lung-cancer-with-brain-metastases-unsuitable-for-resection-or-stereotactic-radiotherapy-quartz-results-from-a-phase-3-non-inferiority-randomised
#15
RANDOMIZED CONTROLLED TRIAL
Paula Mulvenna, Matthew Nankivell, Rachael Barton, Corinne Faivre-Finn, Paula Wilson, Elaine McColl, Barbara Moore, Iona Brisbane, David Ardron, Tanya Holt, Sally Morgan, Caroline Lee, Kathryn Waite, Neil Bayman, Cheryl Pugh, Benjamin Sydes, Richard Stephens, Mahesh K Parmar, Ruth E Langley
BACKGROUND: Whole brain radiotherapy (WBRT) and dexamethasone are widely used to treat brain metastases from non-small cell lung cancer (NSCLC), although there have been no randomised clinical trials showing that WBRT improves either quality of life or overall survival. Even after treatment with WBRT, the prognosis of this patient group is poor. We aimed to establish whether WBRT could be omitted without a significant effect on survival or quality of life. METHODS: The Quality of Life after Treatment for Brain Metastases (QUARTZ) study is a non-inferiority, phase 3 randomised trial done at 69 UK and three Australian centres...
October 22, 2016: Lancet
https://www.readbyqxmd.com/read/27561799/-timing-of-brain-radiation-therapy-impacts-outcomes-in-patients-with-%C3%A2-non-small-cell-lung-cancer-who-develop-brain-metastases
#16
Yang Wang, Jian Fang, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Xiangjuan Ma, Jindi Han, Xiaoling Chen, Guangming Tian, Di Wu, Sen Han, Jieran Long
BACKGROUND: Radiotherapy combined with chemotherapy or molecular targeted therapy remains the standard of treatment for brain metastases from non-small cell lung cancer (NSCLC). The aim of this study is to determine if the deferral of brain radiotherapy impacts patient outcomes. METHODS: Between May 2003 and December 2015, a total of 198 patients with brain metastases from NSCLC who received both brain radiotherapy and systemic therapy (chemotherapy or targeted therapy) were identified...
August 20, 2016: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/27561798/-timing-of-whole-brain-radiotherapy-on-survival-of-patients-with-egfr-mutated-%C3%A2-non-small-cell-lung-cancer-and-brain-metastases
#17
Guimei Liu, Xinyong Zhang, Cuimeng Tian, Guangrong Xia, Ping Liu, Quan Zhang, Xi Li, Hui Zhang, Na Qin, Jinghui Wang, Shucai Zhang
BACKGROUND: There is no high-level evidence for the time of whole brain radiotherapy (WBRT) for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) and brain metastases. The aim of this study is to assess the appropriate timing of WBRT for patients with EGFR-mutated NSCLC and brain metastases (BM). METHODS: There were 78 patients diagnosed with EGFR-mutated NSCLC and BM in Beijing Chest Hospital between August 2009 and May 2015...
August 20, 2016: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/27542716/oligo-recurrence-predicts-favorable-prognosis-of-brain-only-oligometastases-in-patients-with-non-small-cell-lung-cancer-treated-with-stereotactic-radiosurgery-or-stereotactic-radiotherapy-a-multi-institutional-study-of-61-subjects
#18
Yuzuru Niibe, Tetsuo Nishimura, Tetsuya Inoue, Katsuyuki Karasawa, Yoshiyuki Shioyama, Keiichi Jingu, Hiroki Shirato
BACKGROUND: To investigate the prognostic value of oligo-recurrence in patients with brain-only oligometastases of non-small cell lung cancer (NSCLC) treated with stereotactic radiosurgery (SRS) or stereotactic radiotherapy (SRT). METHODS: Patients treated with SRS or SRT for brain-only NSCLC oligometastases in 6 high-volume institutions in Japan between 1996 and 2008 were reviewed. Eligible patients met 1), 2), and 4) or 1), 3), and 4) of the following: 1) NSCLC with 1 to 4 brain metastases on magnetic resonance imaging (MRI) treated with SRS or SRT; 2) control of the primary lesions (thorax) at the time of SRS or SRT for brain metastases (patients meeting this criterion formed the oligo-recurrence group); 3) with SRS or SRT for brain metastases, concomitant treatment for active primary lesions (thorax) with curative surgery or curative stereotactic body radiotherapy (SBRT), or curative chemoradiotherapy (sync-oligometastases group); and 4) Karnofsky performance status (KPS) ≥70...
August 19, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27539328/leptomeningeal-metastases-in-patients-with-nsclc-with-egfr-mutations
#19
Yang-Si Li, Ben-Yuan Jiang, Jin-Ji Yang, Hai-Yan Tu, Qing Zhou, Wei-Bang Guo, Hong-Hong Yan, Yi-Long Wu
INTRODUCTION: Leptomeningeal metastases (LM) have increased in patients with NSCLC, and prognostic factors and outcomes for LM with EGFR gene mutations have not been well studied. METHODS: We retrospectively analyzed patients with lung cancer from January 2011 to June 2015 at our institute. Treatments and clinical outcomes of LM were reviewed. RESULTS: LM were diagnosed in 184 (3.4%) of 5387 patients with lung cancer. Patients with LM harboring EGFR mutations (9...
November 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27536187/comparative-efficacy-of-whole-brain-radiotherapy-with-and-without-elemene-liposomes-in-patients-with-multiple-brain-metastases-from-non-small-cell-lung-carcinoma
#20
Y N Sun, Z Y Zhang, Y C Zeng, F Chi, X Y Jin, R Wu
PURPOSE: We explored and compared the clinical effects of whole-brain radiotherapy (wbrt) with and without elemene liposomes in patients with multiple brain metastases from non-small-cell lung carcinoma (nsclc). METHODS: We retrospectively analyzed 62 patients with multiple brain metastases from nsclc who received wbrt (30 Gy in 10 fractions) at Shengjing Hospital of China Medical University from January 2012 to May 2013. In 30 patients, elemene liposomes (400 mg) were injected intravenously via a peripherally inserted central catheter for 21 consecutive days from the first day of radiotherapy...
August 2016: Current Oncology
keyword
keyword
42875
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"